Literature DB >> 25811315

Decreased Expression of miR-15b in Human Gliomas is Associated with Poor Prognosis.

Guan Sun1, Shushan Yan, Lei Shi, Zhengqiang Wan, Nan Jiang, Min Li, Jun Guo.   

Abstract

MicroRNA-15b (miR-15b) has been demonstrated to suppress proliferation by arresting cell cycle progression and inducing apoptosis in glioma cells. However, the prognostic value of miR-15b expression in human gliomas remains unclear. In the present study, the authors examined the expression profile in glioma specimens and the prognostic value of miR-15b in patients with gliomas. Real-time polymerase chain reaction assay was employed to detect the expression levels of miR-15b in 92 glioma tissues categorized by World Health Organization (WHO) histopathological grades. However, the prognostic value of miR-15b in human glioma has not been evaluated yet. MiR-15b expression in human glioma tissues was distinctly lower than in normal brain tissues. Furthermore, the expression of miR-15b notably decreased with the ascending histopathological grade of gliomas. Additionally, Kaplan-Meier survival analysis showed that low miR-15b expression was associated with poor overall survival in patients with gliomas. Similarly, miR-15b reduction occurred with increasing frequency in glioma patients with lower Karnofsky performance scale (KPS) scores than in those with higher KPS scores. No significant difference was observed between miR-15b expression and gender, age, and tumor location. These findings revealed that a lower expression level of miR-15b was closely related to a shorter overall survival, suggesting that miR-15b could be an intrinsic factor that plays an important role in the malignant progression of gliomas.

Entities:  

Keywords:  glioma; miR-15b; microRNA; overall survival

Mesh:

Substances:

Year:  2015        PMID: 25811315      PMCID: PMC4426309          DOI: 10.1089/cbr.2014.1757

Source DB:  PubMed          Journal:  Cancer Biother Radiopharm        ISSN: 1084-9785            Impact factor:   3.099


  26 in total

1.  MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3.

Authors:  Xuguang Zheng; Michael Chopp; Yong Lu; Benjamin Buller; Feng Jiang
Journal:  Cancer Lett       Date:  2012-11-07       Impact factor: 8.679

2.  Overexpressed miRNA-137 inhibits human glioma cells growth by targeting Rac1.

Authors:  Guan Sun; Ying Cao; Lei Shi; Lihua Sun; Yingyi Wang; Chen Chen; Zhengqiang Wan; Linshan Fu; Yongping You
Journal:  Cancer Biother Radiopharm       Date:  2013-05       Impact factor: 3.099

3.  A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

Authors:  Martin J van den Bent; Lonneke A Gravendeel; Thierry Gorlia; Johan M Kros; Lariesa Lapre; Pieter Wesseling; Johannes L Teepen; Ahmed Idbaih; Marc Sanson; Peter A E Sillevis Smitt; Pim J French
Journal:  Clin Cancer Res       Date:  2011-09-13       Impact factor: 12.531

Review 4.  microRNA and cancer.

Authors:  Mengfeng Li; Jun Li; Xiaofan Ding; Mian He; Shi-Yuan Cheng
Journal:  AAPS J       Date:  2010-04-28       Impact factor: 4.009

5.  MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10.

Authors:  Lihua Sun; Wei Yan; Yingyi Wang; Guan Sun; Hui Luo; Junxia Zhang; Xiefeng Wang; Yongping You; Zhengxiang Yang; Ning Liu
Journal:  Brain Res       Date:  2011-03-16       Impact factor: 3.252

6.  Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells.

Authors:  Lei Shi; Yi Wan; Guan Sun; Xiaoyan Gu; Chunfa Qian; Wei Yan; Shuguang Zhang; Tianhong Pan; Zhimin Wang; Yongping You
Journal:  Neuromolecular Med       Date:  2012-06-19       Impact factor: 3.843

7.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

8.  microRNA-21 promotes tumor proliferation and invasion in gastric cancer by targeting PTEN.

Authors:  Bao Gui Zhang; Jian Fang Li; Bei Qin Yu; Zheng Gang Zhu; Bing Ya Liu; Min Yan
Journal:  Oncol Rep       Date:  2012-01-19       Impact factor: 3.906

9.  Increased expression of microRNA-17 predicts poor prognosis in human glioma.

Authors:  Shengkui Lu; Shuai Wang; Shaomei Geng; Shucheng Ma; Zhaohui Liang; Baohua Jiao
Journal:  J Biomed Biotechnol       Date:  2012-11-19

Review 10.  IDH1 and IDH2 mutations in gliomas.

Authors:  Adam L Cohen; Sheri L Holmen; Howard Colman
Journal:  Curr Neurol Neurosci Rep       Date:  2013-05       Impact factor: 6.030

View more
  12 in total

1.  Low MiR-149 expression is associated with unfavorable prognosis and enhanced Akt/mTOR signaling in glioma.

Authors:  Liang Xue; Yi Wang; Shuyuan Yue; Jianning Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

2.  TERT Genetic Mutations as Prognostic Marker in Glioma.

Authors:  Peiliang Geng; Xiaoxin Zhao; Juanjuan Ou; Jianjun Li; Rina Sa; Houjie Liang
Journal:  Mol Neurobiol       Date:  2016-05-20       Impact factor: 5.590

3.  Prognostic significance of MiR-34a in solid tumors: a systemic review and meta-analysis with 4030 patients.

Authors:  Fanghui Ren; Xin Zhang; Haiwei Liang; Dianzhong Luo; Minhua Rong; Yiwu Dang; Gang Chen
Journal:  Int J Clin Exp Med       Date:  2015-10-15

4.  TRPM2-AS promotes the malignancy of osteosarcoma cells by targeting miR-15b-5p/PPM1D axis.

Authors:  Yingchun Cai; Yudan Yang; Xudong Zhang; Qingqing Ma; Mengyi Li
Journal:  Cell Cycle       Date:  2022-01-31       Impact factor: 5.173

5.  Deregulation of miRNAs in malignant pleural mesothelioma is associated with prognosis and suggests an alteration of cell metabolism.

Authors:  Chiara De Santi; Ombretta Melaiu; Alessandra Bonotti; Luciano Cascione; Gianpiero Di Leva; Rudy Foddis; Alfonso Cristaudo; Marco Lucchi; Marco Mora; Anna Truini; Andrea Tironi; Bruno Murer; Renzo Boldorini; Monica Cipollini; Federica Gemignani; Pierluigi Gasparini; Luciano Mutti; Stefano Landi
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

6.  miR-15b-5p facilitates the tumorigenicity by targeting RECK and predicts tumour recurrence in prostate cancer.

Authors:  Ran Chen; Lu Sheng; Hao-Jie Zhang; Ming Ji; Wei-Qing Qian
Journal:  J Cell Mol Med       Date:  2018-01-24       Impact factor: 5.310

7.  Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status.

Authors:  Bostjan Matos; Emanuela Bostjancic; Alenka Matjasic; Mara Popovic; Damjan Glavac
Journal:  Radiol Oncol       Date:  2018-11-26       Impact factor: 2.991

8.  Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer.

Authors:  Dengbo Ji; Tiancheng Zhan; Ming Li; Yunfeng Yao; Jinying Jia; Haizhao Yi; Meng Qiao; Jinhong Xia; Zhiqian Zhang; Huirong Ding; Can Song; Yong Han; Jin Gu
Journal:  Stem Cell Reports       Date:  2018-11-15       Impact factor: 7.765

Review 9.  MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.

Authors:  Amanda Shea; Varsha Harish; Zainab Afzal; Juliet Chijioke; Habib Kedir; Shahnoza Dusmatova; Arpita Roy; Malathi Ramalinga; Brent Harris; Jan Blancato; Mukesh Verma; Deepak Kumar
Journal:  Cancer Med       Date:  2016-06-10       Impact factor: 4.452

10.  A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.

Authors:  Jian-Hua Zhang; Ruiqin Hou; Yuhualei Pan; Yuhan Gao; Ying Yang; Wenqin Tian; Yan-Bing Zhu
Journal:  J Cell Mol Med       Date:  2020-05-15       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.